5,868 Shares in Quest Diagnostics Incorporated $DGX Acquired by Callan Family Office LLC

Callan Family Office LLC bought a new stake in Quest Diagnostics Incorporated (NYSE:DGX) during the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor bought 5,868 shares of the medical research company’s stock, valued at approximately $1,244,000.

A number of other institutional investors and hedge funds have also added to or reduced their stakes in DGX. Key Financial Inc lifted its position in shares of Quest Diagnostics by 1,728.6% in the 1st quarter. Key Financial Inc now owns 128 shares of the medical research company’s stock worth $25,000 after purchasing an additional 121 shares during the period. Quattro Advisors LLC acquired a new stake in shares of Quest Diagnostics during the fourth quarter worth $25,000. DV Equities LLC acquired a new stake in shares of Quest Diagnostics during the fourth quarter worth $27,000. Sittner & Nelson LLC bought a new position in Quest Diagnostics during the fourth quarter worth $29,000. Finally, McIlrath & Eck LLC bought a new position in Quest Diagnostics during the fourth quarter worth $32,000. Institutional investors and hedge funds own 88.06% of the company’s stock.

Insider Buying and Selling

In other Quest Diagnostics news, CEO J. E. Davis sold 10,000 shares of the firm’s stock in a transaction that occurred on Monday, June 1st. The stock was sold at an average price of $194.14, for a total value of $1,941,400.00. Following the completion of the sale, the chief executive officer owned 132,423 shares of the company’s stock, valued at approximately $25,708,601.22. This trade represents a 7.02% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, SVP Mark E. Delaney sold 1,600 shares of the business’s stock in a transaction that occurred on Tuesday, July 28th. The shares were sold at an average price of $235.18, for a total value of $376,288.00. Following the sale, the senior vice president owned 10,335 shares of the company’s stock, valued at approximately $2,430,585.30. This represents a 13.41% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last three months, insiders have sold 19,747 shares of company stock valued at $3,947,088. 0.88% of the stock is owned by company insiders.

Quest Diagnostics Stock Down 0.0%

Shares of NYSE DGX opened at $244.34 on Monday. The company has a quick ratio of 1.46, a current ratio of 1.59 and a debt-to-equity ratio of 0.72. The firm has a market cap of $26.97 billion, a PE ratio of 25.94, a P/E/G ratio of 2.25 and a beta of 0.56. The company’s fifty day simple moving average is $219.35 and its 200 day simple moving average is $205.29. Quest Diagnostics Incorporated has a 12-month low of $171.18 and a 12-month high of $245.68.

Quest Diagnostics (NYSE:DGX) last posted its quarterly earnings results on Thursday, July 23rd. The medical research company reported $3.12 earnings per share for the quarter, beating the consensus estimate of $2.82 by $0.30. Quest Diagnostics had a net margin of 9.18% and a return on equity of 16.01%. The firm had revenue of $3.04 billion during the quarter, compared to the consensus estimate of $2.97 billion. During the same period in the previous year, the firm posted $2.62 earnings per share. The business’s revenue was up 10.2% compared to the same quarter last year. Quest Diagnostics has set its FY 2026 guidance at 11.050-11.250 EPS. As a group, sell-side analysts forecast that Quest Diagnostics Incorporated will post 11.15 earnings per share for the current fiscal year.

Quest Diagnostics Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Wednesday, October 21st. Investors of record on Tuesday, October 6th will be given a $0.86 dividend. This represents a $3.44 dividend on an annualized basis and a yield of 1.4%. The ex-dividend date of this dividend is Tuesday, October 6th. Quest Diagnostics’s payout ratio is presently 36.52%.

Wall Street Analysts Forecast Growth

A number of analysts have commented on DGX shares. UBS Group upped their price target on shares of Quest Diagnostics from $220.00 to $232.00 and gave the company a “neutral” rating in a research report on Friday, July 24th. Jefferies Financial Group reissued a “buy” rating and issued a $245.00 price objective on shares of Quest Diagnostics in a research report on Thursday, July 23rd. Wall Street Zen raised Quest Diagnostics from a “hold” rating to a “buy” rating in a research note on Tuesday, July 28th. Robert W. Baird upped their target price on Quest Diagnostics from $236.00 to $255.00 and gave the company a “neutral” rating in a research report on Friday, July 24th. Finally, Truist Financial raised their target price on Quest Diagnostics from $225.00 to $250.00 and gave the stock a “hold” rating in a research note on Friday, July 24th. One equities research analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating and seven have issued a Hold rating to the company’s stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $235.31.

About Quest Diagnostics

Quest Diagnostics (NYSE: DGX) is a leading provider of diagnostic information services that supports clinical decision-making for patients, physicians and healthcare organizations. The company operates a network of clinical laboratories and patient service centers that perform a broad range of laboratory tests and diagnostic assays used in routine care, disease diagnosis, monitoring and screening.

Its services span core clinical laboratory testing, anatomic pathology, molecular and genomic diagnostics, infectious disease testing and toxicology.